Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1Phase 1/2 1

Status

Active not recruiting 2Recruiting 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Plasma cell 3

Conditions

Multiple Myeloma 39Recurrence 6Neoplasms, Plasma Cell 3Waldenstrom Macroglobulinemia 2Neoplasms 1Lung Neoplasms 1Leukemia, Plasma Cell 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Lenalidomide 6Dexamethasone 6Cyclophosphamide 5Bortezomib 5fludarabine 3carfilzomib 3belantamab mafodotin 3pomalidomide 2fludarabine phosphate 2Melphalan 2Etoposide 2pembrolizumab 1isatuximab 1elotuzumab 1daratumumab 1Whole-Body Irradiation 1Thalidomide 1Tacrolimus 1Sirolimus 1Resistance Training 1Radiotherapy 1Pharmaceutical Preparations 1Peripheral Blood Stem Cell Transplantation 1Patient Reported Outcome Measures 1Mycophenolic Acid 1Methotrexate 1Exercise 1Equipment and Supplies 1Doxorubicin 1Cyclosporine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Neoplasms, Plasma Cell × carfilzomib × 90 days × Clear all
NCT06152575 2026-06-05

MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)

Pfizer

Phase 3 Recruiting
492 enrolled
Plasma cell

Multiple Myeloma, Neoplasms, Plasma Cell

NCT04822337 2026-04-16

Study of Carfilzomib, Lenalidomide, Dexamethasone and Belantamab Mafodotin in Multiple Myeloma

Wake Forest University Health Sciences

Phase 1/2 Active not recruiting
70 enrolled
Plasma cell

Multiple Myeloma, Neoplasms, Plasma Cell

NCT03500445 2026-04-13

Daratumumab, Carfilzomib, Lenalidomide and Low Dose Dexamethasone (DKRd) in Newly Diagnosed, Multiple Myeloma

University of Chicago

Phase 2 Active not recruiting
75 enrolled
Plasma cell

Multiple Myeloma, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡